Saturday, July 11, 2026

Drug profile · INN

tegafur

tegafur (TEYSUNO) is a thymidylate synthase inhibitor.

EMA: approved Antineoplastic and immunomodulating agents (L01) L01BC53
Patents linked 0
Pipeline programs 5
News articles 0
Drug details — tegafur
Class
Antineoplastic and immunomodulating agents (L01)
Route
Patents
0
Programs
5
Data quality
0.83

Quick answer

tegafur (TEYSUNO) is a thymidylate synthase inhibitor.

Key facts

INN tegafur
Brand TEYSUNO
Mechanism Thymidylate synthase inhibitor
Target DNA
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01BC53

Mechanism of action

Thymidylate synthase inhibitor

Primary target: DNA

Approval history

Authority Status Date
EMA approved

Pipeline programs

  1. D7025C00001 Phase 3 · AstraZeneca · Adenocarcinoma of the biliary tract (intrahepatic or extrahe
  2. ENCITJ-GC01 Phase 3 · Eastern Hepatobiliary Surgery · Gastric Cancer
  3. Tegafur-Gimeracil-Oteracil Potassium Phase 3 · Chinese Academy of · Stomach Neoplasm
  4. Tegafur Gimeracil Oteracil Potassium Capsule Phase 2 · Chinese Academy of · Breast Cancer
  5. cisplatin oxaliplatin tegafur Phase 1 · First People's Hospital · Gastric Cancer

Related & competitor drugs

  1. abiraterone acetate Antineoplastic and immunomodulating agents (L02)
  2. acyclovir Human herpesvirus 1 DNA polymerase inhibitor
  3. acyclovir sodium Human herpesvirus 1 DNA polymerase inhibitor
  4. anagrelide Antineoplastic and immunomodulating agents (L01)
  5. apremilast Antineoplastic and immunomodulating agents (L04)
  6. arsenic trioxide Antineoplastic and immunomodulating agents (L01)

Frequently asked questions

What is tegafur?

tegafur (TEYSUNO) is a thymidylate synthase inhibitor.

What is the brand name for tegafur?

TEYSUNO is a marketed brand name for tegafur. Check FDA Drugs@FDA for the current US label holder and prescribing information.